Affiliation:
1. Mustafa Kemal University , Medical Faculty, Department of Department of Internal Medicine , Hatay , Turkey
2. Mustafa Kemal University , Medical Faculty, Department of Medical Microbiology , Hatay , Turkey
Abstract
Abstract
Aim: The aim of this study was to investigate the in-vitro efficacy of Glycyrrhetinic acid against Helicobacter pylori (H. pylori) strains, as compared with conventional antibacterial agents.
Methods: A total of 41 H. pylori isolates were used, 6 of which were of standard strains (NCTC 1637), 8 of which were drug-sensitive, and 27 were resistant to drugs isolates. Clarithromycin and metronidazole resistance in all strains of H. pylori were determined by the Epsilometer test (E-test) method. MIC study was performed by using microdilution broth method.
Results: Glycyrrhetinic acid was found to be effective against H. pylori NCTC 1637 in doses of 12.0±4.38 µg/mL, while the MIC value of clinical H. pylori isolates susceptible to antimicrobials was 20.8±10.11 µg/ml. It was found that the MIC values for antimicrobial-sensitive clinical H. pylori isolates was higher when compared with H. pylori NCTC 1637 strains. The MIC values of the standard antimicrobial agents against drug-resistant H. pylori strains were higher than H. pylori NCTC 1637 strains and drug-sensitive H. pylori strains. The MIC value was found to be 14.22±7.77 µg/ml for metronidazole, 3.89±1.90 µg/ml for clarithromycin, 2.33±1.0 µg/ml for amoxicillin, 2.44±0.88 µg/ml for levofloxacin and 4.89±2.47 µg/ml for tetracycline, whereas the MIC value of Glycyrrhetinic acid was 26.67±8.0 µg/ml in metronidazole-resistant H. pylori isolates. Besides, MIC values of the antimicrobials and 18ß-Glycyrrhetinic acid among the strains resistant to clarithromycin were as follows: 3.25±2.12 µg/ml for metronidazole, 9.71±4.54 µg/ml for clarithromycin, 2.06±1.32 µg/ml for amoxicillin, 3.88±4.22 µg/ml for levofloaxacin and 3.25±1.04 µg/mL for tetracycline and 22.0±11.11 µg/ml for Glycyrrhetinic acid.
Conclusion: Glycyrrhetinic acid had significant antimicrobial activity against H. pylori strains. Although further in-vivo studies are needed on antimicrobial activity of Glycyrrhetinic acid, increased resistance to drugs currently used in treatment suggests that Glycyrrhetinic acid may be a potential agent for the treatment of H. pylori.
Reference43 articles.
1. 1. Tonkic A, Tonkic M, Lehours P, Megraud F. Epidemiology and diagnosis of Helicobacter pylori infection. Helicobacter 2012; 17:1-8. DOI: 10.1111/j.1523-5378.2012.00975.x10.1111/j.1523-5378.2012.00975.x
2. 2. Silva O, Viegas S, de Mello-Sampayo C, Costa MJ, Serrano R, Cabrita J, Gomes ET. Anti-Helicobacter pylori activity of terminalia macroptera root. Fitoterapia 2012; 83(5):872-6. DOI: 10.1016/j.fitote.2012.03.01910.1016/j.fitote.2012.03.019
3. 3. Choi JH, Yang YJ, Bang CS, Lee JJ, Baik GH. Current Status of the third-line Helicobacter pylori eradication. Gastroenterol Res Pract. 2018; 2018:6523653. DOI: 10.1155/2018/652365310.1155/2018/6523653
4. 4. Chen L, He J, Wang L, Ge Q, Chu H, Chen Y, et al. Efficacies of different proton pump inhibitor-based 14-day bismuth-furazolidone quadruple regimens for the initial eradication of Helicobacter pylori in the southeast coastal region of China:an open-label, randomized clinical trial. Clin Exp Med. 2018 Jun 6. doi:10.1007/s10238-018-0510-9. [Epub ahead of print] DOI: 10.1007/s10238-018-0510-910.1007/s10238-018-0510-9.[Epubaheadofprint]DOI:10.1007/s10238-018-0510-9
5. 5. Wu TS, Hu HM, Kuo FC, Kuo CH. Kaohsiung J. Eradication of Helicobacter pylori infection. Med Sci. 2014; 30(4):167-72. DOI: 10.1016/j.kjms.2013.11.00310.1016/j.kjms.2013.11.003
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献